Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Amgen’s Sensipar Granted Approval by FDA

Tuesday, March 13, 2018   (0 Comments)
Share |



The FDA granted approval for the first generic versions of Amgen’s Sensipar (cinacalcet hydrochloride), a calcium reducer, to treat a thyroid issue for certain patients on dialysis.


In February, a U.S. District Judge shot down Amgen’s attempt to obtain six more months of market exclusivity from the FDA, a decision which the drug manufacturer stated it would appeal.


Sensipar earned Amgen $1.72 billion in 2017, accounting for 9% of the company’s revenue.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal